Medidata has unveiled a new solution called the Medidata Diversity Program, which aims to enhance diversity, equity, and inclusion in clinical trials.
This offering will aid biopharmaceutical and medical device firms, as well as clinical research organisations (CROs), to tackle various barriers that prevent people from taking part in trials.
The Medidata Diversity Program also merges expertise across Medidata AI and Medidata Patient Cloud portfolios to deliver a strategy to attain trial diversity as per regulatory needs.
This approach is executed by raising awareness among patients, streamlining trial access and facilitating decentralisation and a data-powered decision-making process.
The new offering includes an array of solutions such as Medidata AI Intelligent Trials, myMedidata Registries and eConsent, the Medidata Patient Insights Program.
The programme also includes a collaboration of Medidata with Circuit Clinical, a network of clinical trial sites enrolling diverse patients.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
It also incorporates diversity into each step of the process, aiding Medidata to provide diversity and cut down inconsistencies in trial subject enrolment.
Medidata Patient Cloud CEO Anthony Costello said: “Facilitating more diverse participation in clinical trials is a critical and complex challenge, not only for the life sciences industry but for the patients and caregivers participating in the trials.
“The Medidata Diversity Program, the most comprehensive solution to date, will help sponsors and CROs move from awareness about a diversity challenge to planning and solving for it as a standard and sustainable part of their clinical development programmes.”